Safety and Efficacy of Anti-CD47, ALX148 in Combination With Liposomal Doxorubicin and Pembrolizumab in Recurrent Platinum-resistant Ovarian Cancer
University of Pittsburgh
University of Pittsburgh
OHSU Knight Cancer Institute
Mayo Clinic
Yonsei University
Mayo Clinic
Ruhr University of Bochum
AGC Biologics S.p.A.
AGC Biologics S.p.A.
AGC Biologics S.p.A.
Columbia University
Sotio Biotech Inc.
New Mexico Cancer Research Alliance
European Organisation for Research and Treatment of Cancer - EORTC
National Cancer Institute (NCI)
Memorial Sloan Kettering Cancer Center
Swiss Cancer Institute
Janssen Pharmaceutical K.K.